Date:July 11, 2021
Your Name:Kristen E. Schratz
Manuscript Title:_Somatic reversion impacts evolution of myelodysplastic syndromes and acute myeloid leukemia in
short telomere syndromes_
Manuscript number (if known):147598-JCI-CMED-RV-2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	NHLBI T32HL007525	Training grant
	provision of study materials, medical writing, article	Vera and Joseph Dresner Foundation	Grant support
	processing charges, etc.) No time limit for this item.	American Society of Hematology	Grant support
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	None additional	
	in item #1 above).		
3	Royalties or licenses	X None	

4 Consulting fees X None				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	4	Consulting fees	_X None	
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or				
manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	5	lectures, presentations,	_X None	
educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or X None				
testimony Total Control Con		educational events		
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	6		_X None	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or				
8 Patents planned, issued or pending Participation on a Data Safety Monitoring Board or	_			
pending Participation on a Data Safety Monitoring Board or Safety Monitoring Board or	7		_X None	
9 Participation on a Data Safety Monitoring Board or				
9 Participation on a Data Safety Monitoring Board or				
Safety Monitoring Board or	8		_X None	
Safety Monitoring Board or				
Safety Monitoring Board or				
Advisory Board	9		_X None	
		Advisory Board		
10 Leadership or fiduciary role _X None in other board, society,	10	in other board, society,	_X None	
committee or advocacy				
group, paid or unpaid				
11 Stock or stock optionsX None	11	Stock or stock options	_X None	
12 Receipt of equipment, _X None materials, drugs, medical	12		_X None	
writing, gifts or other				
services				
13 Other financial or nonX None financial interests	13		_X None	

Date:July 11, 2021		
Your Name: Valeriya Gaysinskaya		
Manuscript Title: Somatic reversion impacts evolution of myelodysplastic syndromes and acute myeloid leukemia in		
short telomere syndromes_		
Manuscript number (if known):147598-JCI-CMED-RV-2		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	F32HL142207	Training grant
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None	
3	Royalties or licenses	X None	
4	Consulting fees	_X None	

5	Payment or honoraria for lectures, presentations,	_X None	
	speakers bureaus,		
	manuscript writing or educational events		
	Payment for expert testimony	_X None	
-		V N	
7	Support for attending meetings and/or travel	_X None	
8	Patents planned, issued or pending	_X None	
9	Participation on a Data Safety Monitoring Board or	_X None	
	Advisory Board		
	Leadership or fiduciary role in other board, society,	_X None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_X None	
12	Receipt of equipment, materials, drugs, medical	_X None	
	writing, gifts or other		
-	services		
	Other financial or non- financial interests	_X None	
	financial interests		
	manciai interests		

Date:July 11, 2021
Your Name:Zoe L. Cosner
Manuscript Title:_Somatic reversion impacts evolution of myelodysplastic syndromes and acute myeloid leukemia in
short telomere syndromes_
Manuscript number (if known): 147598-JCI-CMED-RV-2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None	
3	Royalties or licenses	X None	
4	Consulting fees	_X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	_X None	
	manuscript writing or educational events		
6	Payment for expert testimony	_X None	
7	Support for attending meetings and/or travel	_X None	
8	Patents planned, issued or pending	_X None	
_			
9	Participation on a Data Safety Monitoring Board or	_X None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	_X None	
	committee or advocacy		
_	group, paid or unpaid		
11	Stock or stock options	_X None	
12	Possint of aguinment	V None	
12	Receipt of equipment, materials, drugs, medical	_X None	
	writing, gifts or other services		
13	Other financial or non- financial interests	_X None	
	manda micresis		

Date:July 11, 2021
Your Name:Emily A. DeBoy
Manuscript Title:_Somatic reversion impacts evolution of myelodysplastic syndromes and acute myeloid leukemia in
short telomere syndromes_
Manuscript number (if known):147598-JCI-CMED-RV-2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	T32 GM136577	Training grant
3	Royalties or licenses	X None	
4	Consulting fees	_X None	

5	Payment or honoraria for lectures, presentations,	_X None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	_X None	
_		V N	
7	Support for attending meetings and/or travel	_X None	
8	Patents planned, issued or pending	_X None	
9	Participation on a Data Safety Monitoring Board or	_X None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	_X None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_X None	
4.5	B		
12	Receipt of equipment, materials, drugs, medical	_X None	
	writing, gifts or other		
	services		
13	Other financial or non-	_X None	
	financial interests		
	financial interests		

Date:July 11, 2021		
Your Name:Zhimin Xiang		
Manuscript Title: Somatic reversion impacts evolution of myelodysplastic syndromes and acute myeloid leukemia in		
short telomere syndromes_		
Manuscript number (if known):147598-JCI-CMED-RV-2		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None	
3	Royalties or licenses	X None	
4	Consulting fees	_X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	_X None	
	manuscript writing or educational events		
6	Payment for expert testimony	_X None	
7	Support for attending meetings and/or travel	_X None	
8	Patents planned, issued or pending	_X None	
_			
9	Participation on a Data Safety Monitoring Board or	_X None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	_X None	
	committee or advocacy		
_	group, paid or unpaid		
11	Stock or stock options	_X None	
12	Possint of aguinment	V None	
12	Receipt of equipment, materials, drugs, medical	_X None	
	writing, gifts or other services		
13	Other financial or non- financial interests	_X None	
	manda micresis		

Date:July 11, 2021			
Your Name: Laura Kasch-Semenza			
Manuscript Title:_Somatic reversion impacts evolution of myelodysplastic syndromes and acute myeloid leukemia in			
short telomere syndromes_			
Manuscript number (if known):147598-JCI-CMED-RV-2			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None	
3	Royalties or licenses	X None	
4	Consulting fees	_X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	_X None	
	manuscript writing or educational events		
6	Payment for expert testimony	_X None	
7	Support for attending meetings and/or travel	_X None	
8	Patents planned, issued or pending	_X None	
_			
9	Participation on a Data Safety Monitoring Board or	_X None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	_X None	
	committee or advocacy		
_	group, paid or unpaid		
11	Stock or stock options	_X None	
12	Possint of aguinment	V None	
12	Receipt of equipment, materials, drugs, medical	_X None	
	writing, gifts or other services		
13	Other financial or non- financial interests	_X None	
	manda micresis		

Date:July 11, 2021		
Your Name: Liliana Florea		
Manuscript Title:_Somatic reversion impacts evolution of myelodysplastic syndromes and acute myeloid leukemia in		
short telomere syndromes_		
Manuscript number (if known):147598-JCI-CMED-RV-2		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	X None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	X None	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	X None	
4	Consulting fees	_X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	_X None	
	manuscript writing or educational events		
6	Payment for expert testimony	_X None	
7	Support for attending meetings and/or travel	_X None	
8	Patents planned, issued or pending	_X None	
_			
9	Participation on a Data Safety Monitoring Board or	_X None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	_X None	
	committee or advocacy		
_	group, paid or unpaid		
11	Stock or stock options	_X None	
12	Possint of aguinment	V None	
12	Receipt of equipment, materials, drugs, medical	_X None	
	writing, gifts or other services		
13	Other financial or non- financial interests	_X None	
	manda micresis		

Date:July 11, 2021		
Your Name: Pali D. Shah		
Manuscript Title:_Somatic reversion impacts evolution of myelodysplastic syndromes and acute myeloid leukemia in		
short telomere syndromes_		
Manuscript number (if known):147598-JCI-CMED-RV-2		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None	
3	Royalties or licenses	X None	
4	Consulting fees	_X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	_X None	
	manuscript writing or educational events		
6	Payment for expert testimony	_X None	
7	Support for attending meetings and/or travel	_X None	
8	Patents planned, issued or pending	_X None	
_			
9	Participation on a Data Safety Monitoring Board or	_X None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	_X None	
	committee or advocacy		
_	group, paid or unpaid		
11	Stock or stock options	_X None	
12	Possint of aguinment	V None	
12	Receipt of equipment, materials, drugs, medical	_X None	
	writing, gifts or other services		
13	Other financial or non- financial interests	_X None	
	manda micresis		

Date:July 11, 2021				
Your Name:Mary Armanios				
Manuscript Title:_Somatic reversion impacts evolution of myelodysplastic syndromes and acute myeloid leukemia in				
short telomere syndromes_				
Manuscript number (if known):147598-JCI-CMED-RV-2				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
	Time frame: Since the initial planning of the work					
1	All support for the present	NCI R01CA225027	Grant support			
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NHLBI R01HL119476	Grant support			
		Commonwealth	Grant support			
		Foundation				
		S&R Foundation	Grant support			
		Williams Foundation	Grant support			
	Time frame: past 36 months					
2	Grants or contracts from	None additional				
	any entity (if not indicated in item #1 above).					
3	Royalties or licenses	X None				

4 Consulting fees X None				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	4	Consulting fees	_X None	
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or				
manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	5	lectures, presentations, speakers bureaus, manuscript writing or	_X None	
educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or X None				
testimony Total Control Con				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	6		_X None	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or				
8 Patents planned, issued or pending Participation on a Data Safety Monitoring Board or	_			
pending Participation on a Data Safety Monitoring Board or Safety Monitoring Board or	7		_X None	
9 Participation on a Data Safety Monitoring Board or				
9 Participation on a Data Safety Monitoring Board or				
Safety Monitoring Board or	8		_X None	
Safety Monitoring Board or				
Safety Monitoring Board or				
Advisory Board	9		_X None	
10 Leadership or fiduciary role _X None in other board, society,	10	in other board, society,	_X None	
committee or advocacy				
group, paid or unpaid				
11 Stock or stock optionsX None	11	Stock or stock options	_X None	
12 Receipt of equipment, _X None materials, drugs, medical	12	materials, drugs, medical writing, gifts or other services	_X None	
13 Other financial or nonX None financial interests	13		_X None	